New questionnaires could help NF1 patients voice appearance concerns
NCT ID NCT06880991
First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 8 times
Summary
This study is developing questionnaires to measure how visible tumors in neurofibromatosis type 1 (NF1) affect patients' appearance concerns. About 110 participants, including children, adults, and caregivers, will complete surveys and join focus groups or interviews to give feedback on two new tools. The goal is to create better ways to assess tumor visibility in clinical trials and care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could provide doctors with better tools to understand how tumor visibility affects patients' quality of life.
- What could go wrong
- This is an early, small study focused on developing questionnaires, not testing a treatment. The results may not apply to all NF1 patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 110 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2025
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
individuals with neurofibromatosis type 1 (NF1) or be the caregiver of a child with NF1 (5-17 years old with plexiform neurofibroma \[pNF\] or 12-17 years old with cutaneous neurofibroma \[cNF\]).
- Ages
-
5 to 120 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Participants must self-report a diagnosis of NF1 OR be the caregiver of a child with NF1 (5-17 years old with plexiform neurofibroma \[pNF\] or 12-17 years old with cutaneous neurofibroma \[cNF\]) The following for the participant or the caregiver of a child, as appropriate: * Participants with NF1 must self-report a pNF and/or cNF tumor(s) that is visible to that individual OR others * Caregivers of a child with NF1 must report a pNF and/or cNF tumor(s) that the child has that is visible to the child OR others * Age requirements: * \>= 8 years old (participants with pNF) * \>= 12 years old (participants with cNF) * \>= 12 years old (participants with pNF and cNF) * \>= 18 years (caregivers) * Access to a device with internet * Ability to understand English and comfort discussing their medical condition in English * The ability of adult participant or caregiver of minor participants to understand and the willingness to sign a written informed consent document EXCLUSION CRITERIA: * Physical or cognitive limitations that would prevent them from being able to participate in a focus group or interview, or unwillingness to do so * Since we will aim to have no less than 25 percent of participants from underrepresented\* groups, individuals from represented groups may not be able to participate after we have reached the maximum target for represented groups. Consistent with best practices for scale development and validation, this will help ensure that the measures are appropriate for people from a variety of backgrounds. \* Underrepresented groups are defined as people who identify as African American or Black, American Indian, Alaska Native, Hispanic/Latine, Native Hawaiian, and other Pacific Islander. * If saturation has been met within a particular age group, potential participants from that completed age group will no longer be eligible.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Neurofibroma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World study tracks Selumetinib's impact on NF1 tumors in children
- Could a cholesterol drug boost reading skills in kids with NF1?
- Antioxidant drug shows promise for kids with NF1
- Can a simple walk test spot motor trouble in kids with NF1?
- Could a cancer drug shrink Children's brain tumors?
- New drug aims to help kids with rare genetic short stature grow taller